Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications

University of California, Los Angeles75 enrolled

Overview

To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.

To assess glaucoma patients' response to treatment with Xiidra (Lifitegrast ophthalmic solution) 5% for ocular surface discomfort caused, in part, by topical glaucoma antihypertensive medications.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Glaucoma Ocular Surface Disease

Interventions

Xiidra (Lifitegrast ophthalmic solution) 5%DRUG

FDA approved lifitegrast opthalmic solution eye drop

Eligibility

Sex: ALLHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Currently using one or more topical glaucoma antihypertensives * Self-described symptoms of ocular surface discomfort * Xiidra is being prescribed as part of the subject's standard care Exclusion Criteria: * History of glaucoma filtration surgery, history of ocular surface surgery (pterygium, conjunctivoplasty, etc.), * current use of topical cyclosporine * current use of topical steroids * incisional ocular surgery within 6 months

Locations (1)

Doheny Eye Center UCLA

Fountain Valley, California, United States

RECRUITING

Outcomes

Primary Outcomes

Change from baseline to week 12 in corneal fluorescein staining score

Change in corneal fluorescein staining score

Time frame: From baseline to Week 12

Change from baseline to week 12 in eye dryness score (EDS)

Change in eye dryness score (EDS)

Time frame: From baseline to Week 12

Change from baseline to week 12 in ocular surface disease index (OSDI) questionnaire score

Change in ocular surface disease index (OSDI) questionnaire score

Time frame: From baseline to Week 12

Secondary Outcomes

Change at intermediate week visits in corneal fluorescein staining score

Change in corneal fluorescein staining score

Time frame: From baseline and at weeks 2, 6, and 12

Change at intermediate week visits in eye dryness score (EDS)

Change in eye dryness score (EDS)

Time frame: From baseline and at weeks 2, 6, and 12

Change at intermediate week visits in ocular surface disease index (OSDI) questionnaire score

Change in ocular surface disease index (OSDI) questionnaire score

Time frame: From baseline and at weeks 2, 6, and 12

Changes in the subcategories of ocular surface disease index (OSDI) questionnaire score at intermediate week visits

Change in subcategory scores of ocular surface disease index (OSDI) questionnaire

Time frame: From baseline and at weeks 2, 6, and 12

Central Contacts

Benjamin B Bert, MD

CONTACT

626-817-4701 BBert@mednet.ucla.edu

Mayra Raygoza

CONTACT

16268174747 Mraygoza@mednet.ucla.edu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.